Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Christopher Johnston Image

      Christopher Johnston, PHD

      Department of Genomic Medicine, Division of Cancer Medicine

      Present Title & Affiliation

      Primary Appointment

      Affiliate Research Investigator, Fred Hutchinson Cancer Center, Seattle, Washington

      Director of Microbial Genomics, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Associate Professor, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2013Cork Institute of Technology, IE, Molecular Microbiology, Ph.D
      2008Cork Institute of Technology (CIT), IE, Applied Biosciences, Cell and Molecular Biology, BSc

      Postgraduate Training

      2014-2016Postgraduate Fellow, Harvard School of Dental Medicine, Boston, Massachusetts
      2013-2016Postdoctoral Fellow, Immunology, and Infectious Disease, The Forsyth Institute, Cambridge, Massachusetts

      Experience & Service

      Faculty Academic Appointments

      Affiliate Assistant Professor, Global Health, University of Washington, 2023 - 2024

      Assistant Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, 2019 - 2024

      Assistant Member of Staff (tenure track), The Forsyth Institute, Cambridge, Massachusetts, 2018 - 2019

      Research Investigator, The Forsyth Institute, Cambridge, Massachusetts, 2016 - 2018

      Other Professional Positions

      Consultant, Seres Therapeutics, 2019 - Present

      Consultant, Azitra Inc, 2019 - Present

      Extramural Institutional Committee Activities

      Member, Genomic Medicine Department Wellness Champion, The University of Texas MD Anderson Cancer Center, 2024 - Present

      ad hoc, NIH Research Enhancement Award (R15) in Oncological Sciences panel review committee member, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Ad Hoc, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) High Impact, Interdisciplinary Science review committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Contributor, Invited Contributor, Surgeon General Report: Oral Health in America: Advances and Challenges, National Institutes of Health. US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, The University of Texas MD Anderson Cancer Center, 2021 - Present

      Member, VIDD Steering Committee, Fred Hutch Cancer Centre, 2021 - 2024

      Advisor, VIDD Faculty Advisory Committee, Fred Hutch Cancer Centre, 2021 - 2024

      Moderator, Invited Moderator, Boston Bacterial Meeting (BBM) 2018. Session: Microbial Engineering, The University of Texas MD Anderson Cancer Center, 2018 - Present

      Member, Institutional Research Committee, Forsyth Institute, 2017 - 2019

      Chair, Institutional Biosafety Committee, Forsyth Institute, 2017 - 2019

      Member, Resources Oversight Committee, Forsyth Institute, 2017 - 2019

      President, Staff Council President, Forsyth Institute, 2016 - 2017

      Ad Hoc Reviewer, Nature Methods, Nature Communications, PLoS Pathogens, Journal of Bacteriology, Msystems, Genome Biology, PLoS ONE, ASM Clinical Microbiology Reviews, The University of Texas MD Anderson Cancer Center, 2014 - 2024

      Honors & Awards

      2024 - PresentMicrobiome Accelerator, Nature
      2023High Impact Interdisciplinary Science review Committee Member, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2021Invited Contributor, Surgeon General Report: Oral Health in America: Advances and Challenges, National Institutes of Health, US Department of Health and Human Services, National Institute of Dental and Craniofacial Research
      2020 - 2024Medical Research Awardee, W. M. Keck Foundation
      2020 - 2022Director’s Transformative Research Awardee, National Institutes of Health (NIH)
      2019Director's Transformative Research Awardee, National Institutes of Health (NIH)
      2018Director' Transformative Research Awardee, National Institutes of Health (NIH)
      2018Invited Moderator, Boston Bacterial Meeting (BBM) 2018. Session: Microbial Engineering
      2017Director's Trnsformative Research Awardee, National Institutes of Health (NIH)
      2012Speaker Travel Award 22nd European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, London, England
      2012Travel Award, Society for General Microbiology (SGM) Spring Conference

      Professional Memberships

      American Association of Cancer Research

      2024 - Present

      International and American Association for Dental Research

      2015 - 2017

      American Society for Microbiology

      2013 - Present

      European Society of Clinical Microbiology and Infectious Diseases

      2010 - Present

      Society for General Microbiology

      2009 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2026. Engineering Microbial Cellular Therapies against Cancer. Invited. Rice-TMC Retreat. Houston, Texas, US.
      2. Advancing Cancer Microbiology: Leveraging the Pangenome, Epigenome, and Essentialome of Tumor-Associated Bacteria. Invited. 2023 IDS/Virology Research Symposium, US.

      Regional Presentations

      1. 2024. Guts, Bugs, and Drugs: Harnessing microbial omics and engineering to understand, treat, and prevent cancer. Invited. South Texas Center for Emerging Infectious Diseases at The University of Texas at San Antonio. San Antonio, TX, US.
      2. 2024. Single cell sequencing to interrogate the impact of bacterial nucleomodulins (DNA-methyl-modifying enzymes) on human cell gene expression. Invited. Pathogen Associated Malignancies Retreat, US.
      3. 2023. Guts, Bugs, and Drugs: Harnessing microbial omics and engineering to understand, treat, and prevent cancer. Invited. James P. Allison Institute 2023 Seminar Series, MD Anderson Cancer Center, US.
      4. 2023. Guts, Bugs, and Drugs: Harnessing microbial omics and engineering to understand, treat, and prevent cancer. Invited. PrimeTR Annual Symposium, MD Anderson Cancer Center. Houston, Texas, US.
      5. 2022. Systematic design of genetic systems for non model organisms (to advance functional interrogations of the human microbiota). Invited. University of Washington, Pathobiology retreat, Center for Urban Horticulture. Seattle, Washington, US.

      National Presentations

      1. 2026. Tumor-infiltrating microbes and their impact on the tumor immune-microenvironment. Invited. AAI Annual Meeting. Boston, Massachusetts, US.
      2. 2025. Systematic design of genetic systems for non-model microbes of clinical and biotechnological relevance. Invited. New England Biolabs Bioinformatics. Houston, Texas, US.
      3. 2025. Diet, Gut, Microbiome, and Cancer. Invited. Endocrine Society's Annual Meeting. San Francisco, California, US.
      4. 2025. Systematic Design of Genetic Systems for Non-Model Microbes of Clinical and Biotechnological Relevance. Invited. 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED). Houston, TX, US.
      5. 2025. Understanding Tumor-infiltrating Microbes in Colorectal Cancer. Invited. Roche Tissue Diagnostics Seminar. Tucson, Arizona, US.
      6. 2025. The Microbiota and Cancer Prevention, Diagnosis, and Treatment. Invited. American Association for Cancer Research (AACR). Chicago, Illinois, US.
      7. 2024. Microbial Cell Therapies: Challenges and Opportunities for Bugs as Drugs. Invited. Society for Immunotherapy of Cancer (SITC). Houston, Texas, US.
      8. 2024. Understanding Intratumoral Microbes in Human Cancers. Invited. SITC Spring Scientific Conference. Miami, Florida, US.
      9. 2024. Tumor Infiltrating Microbes - Their Impact on Cancer Heterogeneity and Predominance of a Genetically Distinct Fusobacterium nucleatum lineage in Colorectal Tumors. Invited. NCI/NIH Microbiome-targeted Intervention Clinical Research Workshop, US.
      10. 2022. Systematic design of genetic systems for non model organisms (to advance functional interrogations of the human microbiota). Invited. Anaerobe 2022, 16th Biennial Congress of the Anaerobe Society of the Americas. Seattle, Washington, US.

      International Presentations

      1. 2025. Systematic design of genetic systems for non-model microbes of clinical and biotechnological relevance. Invited. Mechanisms and Applications of Microbial Gene Editing. Shenzhen, CN.
      Read More
      Less

      Grant & Contract Support

      Title:Engineering Microbial Cellular Therapies against Cancer
      Funding Source:National Institutes of Health
      Role:PI
      Title:Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer
      Funding Source:National Institutes of Health
      Role:PI
      ID:1R01CA288827-01A1
      Title:dvanced genetic systems for Fusobacterium nucleatum in oral and extra-oral pathologies
      Funding Source:National Institutes of Health
      Role:PI
      ID:7R21DE033533-02
      Title:Interrogating the Role of Bacterial Methyl-modifying Enzymes in Pathoadaptation and Host Epigenetic Interference in Cancer
      Funding Source:National Institutes of Health
      Role:PI
      ID:1R01CA290034-01A1

      Selected Publications

      Peer-Reviewed Articles

      1. Venter HJ, Cavanagh JP, Wolden R, Jones D, Roberts RJ, Christensen MO, Zepeda-Rivera M, Johnston CD. Genetic engineering of Staphylococcus haemolyticus: overcoming restriction-modification barriers and targeting virulence genes. Microb Genom 12(7), 2026. e-Pub 2026. PMID: 42522685.
      2. Bouzek HK, Zepeda-Rivera MA, Srinivasan S, Lee EM, Strenk SM, Jones DS, McMahon EF, Fiedler TL, Kostovski M, France MT, Ravel J, Fredricks DN, Johnston CD. A syntenic pangenome of Gardnerella reveals novel plasmids and phage, taxonomic boundaries, and species-level stratification of metabolic and virulence potential. Nat Commun, 2026. e-Pub 2026. PMID: 42323284.
      3. Venter HJ, Cavanagh JP, Wolden R, Jones D, Roberts RJ, Christensen MO, Zepeda-Rivera M, Johnston CD. Genetic engineering of Staphylococcus haemolyticus : Overcoming Restriction-Modification Barriers and Targeting Virulence Genes. bioRxiv, 2026. e-Pub 2026. PMID: 41676585.
      4. Zepeda-Rivera MA, Eisele Y, Baryiames A, Wu H, Mengoni C, Piccinno G, McMahon EF, LaCourse KD, Jones DS, Hauner H, Minot SS, Segata N, Dewhirst FE, Johnston CD, Bullman S. Fusobacterium sphaericum sp. nov., isolated from a human colon tumor adheres to colonic epithelial cells and induces IL-8 secretion. Gut Microbes 17(1):2442522, 2025. e-Pub 2025. PMID: 39722539.
      5. Morad G, Damania AV, Melendez B, Singh BB, Veguilla FJ, Soto RA, Hoballah YM, Sahasrabhojane PV, Wong MC, Ahmed MM, Rico RN, Lewis KN, Wani K, Shamsutdinova DD, Lazcano Segura RN, Ingram DR, Goethe EA, Day A, Flores II, McDaniel LK, Chelvanambi M, Johnson SB, Dimitriou F, Gupta P, Oberai S, Zal MA, Doss P, Jamal MA, Hayase E, Wathoo C, Norberg LM, Jenkins SL, Nass S, Gumin J, Long L, Yang J, Bradley GR, Bekal MP, Dono AG, Pichardo-Rojas PS, Andrewes SW, Ballester LY, Losh JS, Liang J, Huo L, Nielsen DC, Parker Kerrigan BC, Brastianos PK, Fowlkes NW, Chang CC, Jenq RR, Gomez-Manzano C, Huse JT, Davies MA, Lazar AJ, Bhat KP, Tandon N, Esquenazi Y, Peterson CB, Puduvalli VK, Lang FF, Johnston CD, Bullman S, Ajami NJ, Ferguson SD, Wargo JA. Microbial signals in primary and metastatic brain tumors. Nat Med 31(11):3675-3688, 2025. e-Pub 2025. PMID: 41238915.
      6. Gavate R, Zepeda-Rivera MA, Jones DS, LaCourse KD, Bullman S, Johnston CD. Complete genome sequence of Peptostreptococcus anaerobius SB204, isolated from a human colonic adenocarcinoma. Microbiol Resour Announc:e0080425, 2025. e-Pub 2025. PMID: 41105497.
      7. Galeano Nino JL, Ponath F, Ajisafe VA, Becker CR, Kempchinsky AG, Zepeda-Rivera MA, Gomez JA, Wu H, Terrazas JG, Bouzek H, Cromwell E, Chanana P, Wong M, Damania A, White MG, You YN, Kopetz S, Ajami NJ, Wargo JA, Johnston CD, Bullman S. Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. Cancer Cell, 2025. e-Pub 2025. PMID: 41106380.
      8. Lewis KN, Zepeda-Rivera MA, Baryiames AA, Jones DS, LaCourse KD, Bullman S, Johnston CD. Complete genome sequence for Slackia exigua strain SB208, isolated from a human colonic adenocarcinoma. Microbiol Resour Announc 14(10):e0044525, 2025. e-Pub 2025. PMID: 40970704.
      9. Zepeda-Rivera MA, Ponath F, Lewis KN, Gavate RP, Dewhirst FE, Tomida J, Kawamura Y, Tanaka K, Bullman S, Johnston CD. Genome sequences of eight Fusobacterium watanabei sp. isolates. Microbiol Resour Announc 14(8):e0013225, 2025. e-Pub 2025. PMID: 40719440.
      10. Zepeda-Rivera MA, Ponath F, Lewis KN, Gavate RP, Dewhirst FE, Tomida J, Kawamura Y, Tanaka K, Bullman S, Johnston CD. Complete genome sequences of Fusobacterium watanabei sp. isolates. bioRxiv, 2025. e-Pub 2025. PMID: 40196618.
      11. Bouzek H, Srinivasan S, Jones DS, McMahon EF, Strenk SM, Fiedler TL, Fredricks DN, Johnston CD. A Syntenic Pangenome for Gardnerella Reveals Taxonomic Boundaries and Stratification of Metabolic and Virulence Potential across Species. bioRxiv, 2025. e-Pub 2025. PMID: 40027674.
      12. Zepeda-Rivera MA, Eisele Y, Baryiames A, Wu H, Mengoni C, Piccinno G, McMahon EF, LaCourse KD, Jones DS, Hauner H, Minot SS, Segata N, Dewhirst FE, Johnston CD, Bullman S. Fusobacterium sphaericum sp. nov. , isolated from a human colon tumor, adheres to colonic epithelial cells and induces IL-8 secretion. bioRxiv, 2024. e-Pub 2024. PMID: 37398369.
      13. Zepeda Rivera, M, Minot, SS, Bouzek, H, Wu, H, Blanco-Míguez, A, Manghi, P, Jones, DS, LaCourse, KD, Wu, Y, McMahon, EF, Park, SN, Lim, YK, Kempchinsky, AG, Willis, AD, Cotton, SL, Yost, SC, Sicinska, E, Kook, JK, Dewhirst, FE, Segata, N, Bullman, S, Johnston, CD. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature 628(8007):424-432, 2024. e-Pub 2024. PMID: 38509359.
      14. Johnston CD, Bullman S. Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy resistance. Trends Cancer 10(2):97-99, 2024. e-Pub 2024. PMID: 38242824.
      15. Johnston, CD, Goetting-Minesky, MP, Kennedy, K, Godovikova, V, Zayed, SM, Roberts, RJ, Fenno, JC. Enhanced transformation efficiency in Treponema denticola enabled by SyngenicDNA-based plasmids lacking restriction–modification target motifs. Molecular Oral Microbiology 38(6):455-470, 2023. e-Pub 2023. PMID: 37880921.
      16. Galeano Niño, JL, Wu, H, LaCourse, KD, Srinivasan, H, Fitzgibbon, M, Minot, SS, Sather, C, Johnston, CD, Bullman, S. INVADEseq to identify cell-adherent or invasive bacteria and the associated host transcriptome at single-cell-level resolution. Nature protocols 18(11):3355-3389, 2023. e-Pub 2023. PMID: 37789194.
      17. Grabner, E, Stare, E, Fanedl, L, Zorec, M, Jones, DS, Johnston, CD, Avguštin, G, Accetto, T. Expanding the rumen Prevotella collection. Systematic and Applied Microbiology 46(4), 2023. e-Pub 2023. PMID: 37295348.
      18. O'Brien VP, Jackson LK, Frick JP, Rodriguez Martinez AE, Jones DS, Johnston CD, Salama NR. Helicobacter pylori Chronic Infection Selects for Effective Colonizers of Metaplastic Glands. mBio 14(1):e0311622, 2023. e-Pub 2023. PMID: 36598261.
      19. Galeano Niño, JL, Wu, H, LaCourse, KD, Kempchinsky, AG, Baryiames, AA, Barber, B, Futran, N, Houlton, J, Sather, C, Sicinska, E, Taylor, A, Minot, SS, Johnston, CD, Bullman, S. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611(7937):810-817, 2022. e-Pub 2022. PMID: 36385528.
      20. LaCourse, KD, Zepeda Rivera, M, Kempchinsky, AG, Baryiames, AA, Minot, SS, Johnston, CD, Bullman, S. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Reports 41(7), 2022. e-Pub 2022. PMID: 36384132.
      21. Rosconi, F, Rudmann, E, Li, J, Surujon, D, Anthony, J, Frank, M, Jones, DS, Rock, CO, Rosch, JW, Johnston, CD, van Opijnen, T. A bacterial pan-genome makes gene essentiality strain-dependent and evolvable. Nature microbiology 7(10):1580-1592, 2022. e-Pub 2022. PMID: 36097170.
      22. Stepanovica, M, Zepeda Rivera, M, McGlinchey, AS, Baryiames, AA, Jones, DS, LaCourse, KD, Bullman, S, Johnston, CD. Complete Genome Sequence of Morganella morganii CTX51T, Isolated from a Human Cecal Adenocarcinoma. Genome Announcements 11(4), 2022. e-Pub 2022. PMID: 35254123.
      23. McGlinchey, AS, Zepeda Rivera, M, Stepanovica, M, Baryiames, AA, Jones, DS, LaCourse, KD, Bullman, S, Johnston, CD. Complete Genome Sequence of Clostridium cadaveris IFB3C5, Isolated from a Human Colonic Adenocarcinoma. Genome Announcements 11(3), 2022. e-Pub 2022. PMID: 35234492.
      24. Ouellette, M, Bejian, AA, Chen, T, Jones, DS, Johnston, CD, Dewhirst, FE. Complete Genome Sequence of Arachnia rubra Strain DSM 100122T, a Cultured Member of the Human Oral Microbiome. Genome Announcements 10(48), 2021. e-Pub 2021. PMID: 34854708.
      25. Ramos, SF, Brugger, SD, Escapa, IF, Skeete, CA, Cotton, SL, Eslami, SM, Gao, W, Bomar, L, Tran, TH, Jones, DS, Minot, SS, Roberts, RJ, Johnston, CD, Lemon, KP. Genomic Stability and Genetic Defense Systems in Dolosigranulum pigrum, a Candidate Beneficial Bacterium from the Human Microbiome. mSystems 6(5), 2021. e-Pub 2021. PMID: 34546072.
      26. Deptula P, Laine P, Paulin L, Auvinen P, Roberts RJ, Johnston CD, Varmanen P. Complete Genome Sequences and Methylome Analyses of Cutibacterium acnes subsp. acnes Strains DSM 16379 and DSM 1897(T). Microbiol Resour Announc 9(29), 2020. e-Pub 2020. PMID: 32675190.
      27. Bor B, Collins AJ, Murugkar PP, Balasubramanian S, To TT, Hendrickson EL, Bedree JK, Bidlack FB, Johnston CD, Shi W, McLean JS, He X, Dewhirst FE. Insights Obtained by Culturing Saccharibacteria With Their Bacterial Hosts. J Dent Res 99(6):685-694, 2020. e-Pub 2020. PMID: 32075512.
      28. Johnston CD, Cotton SL, Rittling SR, Starr JR, Borisy GG, Dewhirst FE, Lemon KP. Systematic evasion of the restriction-modification barrier in bacteria. Proc Natl Acad Sci U S A 116(23):11454-11459, 2019. e-Pub 2019. PMID: 31097593.
      29. Juarez JF, Lecube-Azpeitia B, Brown SL, Johnston CD, Church GM. Biosensor libraries harness large classes of binding domains for construction of allosteric transcriptional regulators. Nat Commun 9(1):3101, 2018. e-Pub 2018. PMID: 30082754.
      30. Singh R, Hui T, Matsui A, Allahem Z, Johnston CD, Ruiz-Torruella M, Rittling SR. Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin. Immunology 150(1):74-86, 2017. e-Pub 2017. PMID: 27599164.
      31. Johnston CD, Skeete CA, Fomenkov A, Roberts RJ, Rittling SR. Restriction-modification mediated barriers to exogenous DNA uptake and incorporation employed by Prevotella intermedia. PLoS One 12(9):e0185234, 2017. e-Pub 2017. PMID: 28934361.
      32. Endersen L, Guinane CM, Johnston C, Neve H, Coffey A, Ross RP, McAuliffe O, O'Mahony J. Genome analysis of Cronobacter phage vB_CsaP_Ss1 reveals an endolysin with potential for biocontrol of Gram-negative bacterial pathogens. J Gen Virol 96(Pt 2):463-477, 2015. e-Pub 2015. PMID: 25371517.
      33. Matsui A, Jin JO, Johnston CD, Yamazaki H, Houri-Haddad Y, Rittling SR. Pathogenic bacterial species associated with endodontic infection evade innate immune control by disabling neutrophils. Infect Immun 82(10):4068-79, 2014. e-Pub 2014. PMID: 25024367.
      34. Feeney A, Johnston CD, Govender R, O'Mahony J, Coffey A, Sleator RD. Analysis of the role of the Cronobacter sakazakii ProP homologues in osmotolerance. Gut Pathog 6:15, 2014. e-Pub 2014. PMID: 24910715.
      35. Feeney A, Johnston CD, Lucid A, O'Mahony J, Coffey A, Lucey B, Sleator RD. The role of the Cronobacter sakazakii ProP C-terminal coiled coil domain in osmotolerance. Gut Pathog 6(1):46, 2014. e-Pub 2014. PMID: 25530808.
      36. Johnston CD, Bannantine JP, Govender R, Endersen L, Pletzer D, Weingart H, Coffey A, O'Mahony J, Sleator RD. Enhanced expression of codon optimized Mycobacterium avium subsp. paratuberculosis antigens in Lactobacillus salivarius. Front Cell Infect Microbiol 4:120, 2014. e-Pub 2014. PMID: 25237653.
      37. Johnston C, Douarre PE, Soulimane T, Pletzer D, Weingart H, MacSharry J, Coffey A, Sleator RD, O'Mahony J. Codon optimisation to improve expression of a Mycobacterium avium ssp. paratuberculosis-specific membrane-associated antigen by Lactobacillus salivarius. Pathog Dis 68(1):27-38, 2013. e-Pub 2013. PMID: 23620276.
      38. Johnston C, Coffey A, O' Mahony J, Sleator RD. Development of a novel oral vaccine against Mycobacterium avium paratuberculosis and Johne disease: a patho-biotechnological approach. Bioeng Bugs 1(3):155-63, 2010. e-Pub 2010. PMID: 21326921.

      Review Articles

      1. Zepeda-Rivera MA, Dewhirst FE, Bullman S, Johnston CD. Addressing controversy in Fusobacterium nomenclature: what exactly does "F. nucleatum" refer to?. Gut Microbes 17(1):2514797, 2025. e-Pub 2025. PMID: 40464118.
      2. Johnston CD, Wargo JA. Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol 45(12):931-933, 2024. e-Pub 2024. PMID: 39603891.
      3. LaCourse, KD, Johnston, CD, Bullman, S. The relationship between gastrointestinal cancers and the microbiota. The Lancet Gastroenterology and Hepatology 6(6):498-509, 2021. e-Pub 2021. PMID: 33743198.

      Other Articles

      1. Grabner, E, Stare, E, Fanedl, L, Zorec, M, Jones, DS, Johnston, CD, Avguštin, G, Accetto, T Corrigendum to “Expanding the rumen Prevotella collection. Systematic and Applied Microbiology 46(5), 2023. PMID: 37669882.
      2. Johnston, CD, Bullman, S The tumour-associated microbiome. Nature Reviews Gastroenterology and Hepatology 19(6):347-348, 2022. PMID: 35361914.
      3. Bullman, S, Eggermont, AM, Johnston, CD, Zitvogel, L Harnessing the microbiome to restore immunotherapy response. Nature Cancer 2(12):1301-1304, 2021. PMID: 35121929.
      Read More
      Less

      Patient Reviews


      CV information above last modified August 20, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Johnston Laboratory

      • Genomic Medicine department

      • Cancer Medicine division

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top